Chuck Drucker

In February 2021 we published an article in 

 entitled, “Self-collection of Blood Specimens in Clinical Trials."

 The article described how the pandemic accelerated interest in decentralized clinical trial (DCT) approaches, including the use of blood self-collection devices to enable a clinical trial participant to collect their own blood without having to visit an investigator site or have a healthcare worker visit them at home. We went on to describe innovative self-collection devices and the operational and patient burden considerations associated with such an approach.

From an operational perspective, we reviewed the various collection approaches, the need for assay development (since the devices collect capillary blood vs. venous blood, which is typically used for laboratory safety testing), the device regulatory framework, kit building, centrifugation, and direct to and from participant processes. As for patient burden, we discussed considerations around study design, tests required, pain tolerance, collection time and complexity requirements, participant use of collection devices and centrifuges, participant logistics considerations, and participant support needs. Finally, we described a correlation feasibility study we conducted, which demonstrated good correlation between venous and capillary blood specimens for a 12-analyte chemistry panel using a Tasso-SST (serum separator tube) self-collection device and a Sandstone Diagnostics portable centrifuge.

Since then, we have continued to perform scientific and operational feasibility studies to determine how we could make a safety testing panel available in clinical trials via at-home self-collection of blood specimens. While a finger prick via a lancet and dripping blood into a tube may be technically possible for at home collection, participant feedback indicated that this approach was less preferred and more painful than venous phlebotomy and the shoulder based innovative blood collection devices, like those produced by Tasso, therefore we focused our research on the Tasso+ device.

Most safety lab tests require venous blood specimens to be centrifuged within one hour after specimen collection and prior to shipment to the laboratory for testing. Fortunately, there are small portable centrifuges on the market and others under development, which are designed for at-home use. Clinical trial laboratories can develop robust processes to enable shipment of centrifuges to participants, clear participant instructions, and shipment of centrifuges back to labs. And labs can develop centrifuge reutilization programs, so that the right number of centrifuges are available at the right time for a study, to optimize cost and simplify logistics.

With the intention of reducing patient burden and operational complexity regarding centrifugation, we wondered if it would be possible to generate test results that correlate, if participants ship specimens to the lab without centrifugation, and have the lab staff perform the centrifugation, versus the standard process of investigator site staff performing centrifugation prior to specimen shipment to the lab. While we assumed this would not work for all analytes, the team felt it would be worthwhile to determine feasibility.

As such, we embarked upon a feasibility study to compare the results from three specimen collection approaches to help determine if lab centrifugation of specimens for safety (chemistry) testing is feasible. Approach 1 utilized venous blood centrifuged immediately, approach 2 utilized capillary blood, obtained via the Tasso+ SST device centrifuged within one hour of collection, and approach 3 also utilized capillary blood, via the Tasso+ SST device, but it was not centrifuged and instead shipped to the Q2 Solutions laboratory, where the specimens were centrifuged. The specimen sets were tested on the Roche Cobas 8000/c702 for a 15-analyte chemistry panel, including: Alanine transaminase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Total bilirubin, Direct bilirubin, Total protein, Albumin, Glucose, Sodium, Potassium, Chloride, Magnesium, Calcium, Phosphorus, Enzymatic Creatinine.

Process optimization—refrigerated shipments

We observed good correlation between the venous and Tasso SST capillary specimens that were centrifuged immediately at the investigator site. However, some capillary specimens that were not centrifuged at the investigator site arrived at the laboratory hemolyzed, which for some analytes (e.g. AST and ALT) would result in result cancellation. Through experimentation, we found that refrigerated shipment of specimens enabled the non-centrifuged specimens to arrive in an acceptable condition for testing. Upon testing the specimens, the results also showed acceptable correlation with results from the other two approaches (routine venipuncture and centrifuging Tasso SST samples at site) for most analytes studied.

With the success of the feasibility study, we conducted a validation study with a similar design around the three specimen types, but this time with 25 different analytes. At the time of publication, we have successfully completed the validation report for a 7-analyte liver safety panel, including Total Protein, Albumin, Alkaline phosphatase (ALP), Alanine transaminase (ALT), Aspartate transaminase (AST), Direct Bilirubin, and Total Bilirubin. The results for the 7-analyte liver safety panel showed good correlation and good sample stability to provide enough time to ship samples from a participant’s home to the laboratory. Details are available upon request. The report for the other 18-analytes is under development. It is important to note that the validation report is based on an alternate sample type validation performed according to industry guidelines such as Clinical and Laboratory Standards Institute (CLSI) EP35 (Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures). We encourage clinical trial sponsors to discuss the approach, and share the validation report, with regulators prior to using for diagnostic and patient care purposes.

The term “Liver function tests,” is a historical misnomer to describe Liver Chemistry Testing, as the assays performed not only access the function of the liver (synthetic function) but also hepatocellular injury and the hepatobiliary tract conditions. Testing and monitoring of the various proteins made by the liver is important for determining hepatic health, especially in subjects enrolled in clinical trials.

 Most drugs are metabolized by the liver and monitoring early damage is essential in preventing Drug Induced Liver Injury which may lead to liver transplant or even death.

 Levels that are higher or lower than normal can indicate liver problems. Some common liver chemistry tests include:

Alanine transaminase (ALT). ALT is an enzyme found in the liver cells and convert alanine into pyruvate to provide energy for the liver cells. When the liver is damaged, ALT is released into the bloodstream and levels increase.

Aspartate transaminase (AST). AST is an enzyme that is involved in gluconeogenesis in the liver Like ALT, AST is normally present in blood at low levels. An increase in AST levels may indicate liver damage, disease, or muscle damage.

Alkaline phosphatase (ALP). ALP is an enzyme found in the liver and bone and is important for breaking down proteins. ALP made in the liver, bone, kidney, small intestine, and other organs of the body and thus is non-specific; however elevated levels may indicate liver damage or cholestasis or certain bone diseases.

Albumin and total protein are proteins used to measure function of the liver. These are produced in the liver to be secreted into the plasma. Albumin is the major protein in the blood and helps transport many important molecules the body needs to regulate metabolic processes. Lower-than-normal levels of albumin and total protein may indicate the failure of the liver to produce these important proteins, thus liver damage or disease.

Bilirubin, is a byproduct of the normal breakdown of red blood cells. Bilirubin normally is processed in the liver and is excreted in stool. Elevated levels of bilirubin (jaundice) indicate liver damage of the hepatobiliary tract or disease or certain types of anemia.

Measuring the transaminases (ALT/AST) and bilirubin are critically important in determining if a drug is responsible for causing Drug Induced Liver Injury (DILI). DILI is responsible for the majority of liver transplants, thus being able to assess liver chemistries before DILI occurs is critical in pharmaceutical trials.

Operational and patient-burden oriented processes

At the same time as investigating analyte correlation feasibility and validation, we examined operational and patient burden-oriented processes. As with the scientific work, our operational work began with a feasibility study to work through how a self-collection visit would impact clinical trial laboratory processes, investigator site processes, and most importantly patient burden. After the feasibility work, we formalized the processes as described below.

: Based on information in the validation report and the specimen collection instructions a test code was created to enable the laboratory systems to generate lab reports and reference range alerts.

The Tasso direct to participant (DtP) investigator kit ordering portal

: The Tasso kit ordering portal was enhanced to enable a clinical trial investigator to order a kit and send it directly to a study participant, while capturing the necessary details for a clinical trial laboratory to accession samples. The portal is required to be compliant with regulations and assure that the laboratory and many study team personnel do not have access to personally identifiable information (PII).

: Information from the portal is printed onto paper requisitions which are included in the kits that are sent to study participants. In addition, unique bar codes are printed onto tube labels. These steps enable the laboratory to accession samples according to standard procedures. Electronic approaches to this process are also under consideration.

: Participants are provided with written and video instructions for use regarding the proper way to prepare for the specimen collection, the use of the Tasso+ device, packaging, and shipping instructions. Some study teams may require that investigator site personnel provide training on site or via video call to assure proper collection, packaging, and shipment and to help participants become confident with the process.

: Two options are available to mitigate the risk of participants not being able to collect a specimen via a potential device failure. First, it is possible to ship out a new device within 24 hours of receipt of an order for a replacement from an investigator site. Second, it is possible to include two devices in the original kit order.

: To minimize patient burden, we chose not to require participants to register devices via a web portal, but instead they are provided with pre-printed patient-specific requisitions and tubes. Beyond self-specimen collection and shipment, the only other requirement is for the participant to enter the time and date of collection on the requisition form.

: Shipping specimens in a cool refrigerated state, via a commercially available packaging solution, reduces patient burden by eliminating the need for at home centrifugation for the liver panel analytes above.

: Prior to specimen collection participants are asked to schedule their specimen pick up with the courier to occur on the same day as specimen collection. It is recommended that pickups be scheduled between Monday and Thursday only when the participant is available to give the sample directly to the courier.

: The blood specimens arrive at the laboratory in a 0.6 mL SST Tube where they are accessioned into the laboratory information system and sent to the lab for centrifugation and then testing. Lab reports, alerts, queries, and data transfers are managed via standard processes.

: The role of the clinical trial investigator remains unchanged. The investigator remains accountable for specimen collection, as well as patient care and support, including questions about how to utilize the device or ship the samples. Lab reports and alerts are provided to investigators just like any other lab test and investigators remain accountable for queries.

: Currently the offering is only available in the United States of America, but plans are in place to expand geographically.

: The table below compares the fee structure of an investigator site specimen collection, home healthcare specimen collection, and self-collection. The table assumes a single specimen collection visit for a liver panel. The fees for the self-collection liver panel process are far less, at least an order of magnitude less, than a nurse visit to a participant’s home. In the US there are some phlebotomist networks, and the fee for a phlebotomist visit with courier fees and testing are similar to the overall fees for the self-collection liver panel.

: Identity verification is available by having investigator site staff observe a patient via video conference. In addition, digital identity verification solutions, some of which have grown out of a need to manage COVID-19 testing, have become available. Finally, colleagues have opined about the concept of genetic identity verification as well as advanced analytics.

: Since the Tasso system can capture a participant’s email address or mobile phone number, it is possible for the system to send reminders to participants. Alternatively, Decentralized Clinical Trial (DCT) suppliers may manage patient reminders.

Laboratory scientists and operations teams around the world continue to collaborate to find ways to drive increased utilization of the self-collection of blood specimens for laboratory testing in clinical trials and diagnostics. Further innovation, including in the areas below, may help to drive adoption.

: Clinical trial protocols may require many tubes of blood and a dozen or more panels and tests per visit. How could this be accomplished via self-collection devices, which collect relatively small volumes of blood? Would a participant have to use a dozen or more devices and manage a convoluted specimen processing and shipping process?This doesn’t seem practical. A significant reason why the self-collection liver panel has become a reality relates to the work that Roche Diagnostics has done to minimize the sample volume requirements for their automated chemistry analyzers. It’s also why we were able to test 25 analytes using as little as about 600 µL of whole blood (200-300 µL serum). If Roche Diagnostics and other instrument manufacturers can continue to innovate by reducing sample volume requirements while maintaining automated approaches, the chances of expanding the self-collection test menu, to meet the needs of clinical trial protocols, will be improved.

: Some tests that require immediate centrifugation may not correlate to centrifugation at the laboratory, so the operational and patient burden considerations around the distribution of small portable centrifuges to trial participants, use, and return of centrifuges to the laboratory will have to be addressed.

 Some sample types have very limited stability and require freezing soon after specimen collection. Today, in many jurisdictions, it is possible for a courier to bring dry ice to a participant’s home to pick up specimens, however, to date the authors are unaware of instances in which this has been attempted in a self-collection process utilized for data reported in a clinical trial.

: Tasso, along with other innovative device suppliers like Neoteryx and Drawbridge Health, offer solutions that collect blood onto porous material, and others provide participant oriented dried blood cards and lancets. These dried blood approaches enable improved sample stability. There has been some success with this approach regarding Pharmacokinetics (PK),

Can self-collection of blood in clinical trials improve patient recruitment and retention?

 That’s exactly what the non-profit Patient Centric Sampling Interest Group (PCSIG) is trying to determine via a carefully constructed clinical trial.

While the creation of the first ever self-collection 7-analyte liver safety panel for clinical trials via the Tasso+ device is a considerable achievement, it is recognized that for the use of self-collection of blood in clinical trials to gain further acceptance a much broader test menu is required. Many clinical trial testing and commercial diagnostic testing colleagues are performing feasibility studies related to many kinds of tests with the aim of making additional tests available via self-collection approaches in clinical trials and healthcare.

, Vice President, Strategy & Corporate Development, 

, Global Director, Scientific Harmonization, 

, PhD, Decentralized Trials Solutions Manger, 

, Director, Decentralized Trial Solutions, 

, PhD, D-ABMLI, MBA, FACB, Senior Laboratory Director, 

, PhD, Principal Scientist Regulatory Operations; all with Q² Solutions

Drucker, Chuck, et al. “Self-Collection of Blood Specimens in Clinical Trials.” Applied Clinical Trials Online, 

https://www.appliedclinicaltrialsonline.com/view/self-collection-of-blood-specimens-in-clinical-trials

Wickremsinhe, Enaksha. “Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver Chemistry.” Academic.oup.com, T

he Journal of Applied Laboratory Medicine

https://academic.oup.com/jalm/advance-article/doi/10.1093/jalm/jfac127/6931879

M Ammar Kalas, Luis Chavez, Monica Leon, Pahnwat Tonya Taweesedt, Salim Surani. World Journal of Hepatology (2021) 13:1688-1698

Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). July 2009

Williams, Kathi J, et al. “Assessment of Low Volume Sampling Technologies: Utility in Nonclinical and Clinical Studies.” 

, vol. 13, no. 9, 2021, pp. 679–691., https://doi.org/10.4155/bio-2021-0027.

Hendelman, Tess, et al. “Self-Collection of Capillary Blood Using Tasso-SST Devices for Anti-SARS-Cov-2 IGG Antibody Testing.” PLOS ONE, Public Library of Science, 21 Sept. 2021, 

https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0255841

Articles

Laboratory services organization focuses on easing patient and site burden with improved collection device.

At-home Self-collection of Blood Specimens for Safety Lab Testing in Clinical Trials via the Tasso+ Device

Companies like Ancestry.com and 23andMe have helped make the self-collection of DNA via saliva relatively commonplace. In clinical trials self-collection of DNA via saliva and cheek swabs, as well as stool self-collection are also relatively common. This article focuses on devices that can potentially enable patients to collect their own blood in their homes for clinical trials. Through technological innovation there are several devices under development for potential self-collection of dried blood spot and liquid blood samples.

Over the past several years, and more recently due to the COVID-19 global pandemic, patient centric trial designs have accelerated specimen collection either at home via visiting nurses or phlebotomists, or at retail locations, like a pharmacy or a Quest Diagnostics patient service center.

Like home specimen collection, self-collection of specimens in clinical trials, sometimes referred to as patient-centric sampling, may make participation in clinical trials more convenient for patients. This paradigm involves sending specimen collection devices directly to patients, who then collect their own blood specimen and send it to a laboratory for testing. Technologies and solutions are under development to enable self-collection without the need of a phlebotomist or nurse home visit or a patient visit to an investigator site.

Self-collection of blood specimens in clinical trials starts out like specimen collection at investigator sites in that a protocol is developed and patient burden is strongly considered. Most of the time a central laboratory sets up a study database, and creates specimen collection kits that are study, investigator, and visit specific, and include requisitions and shipping materials. From there the processes diverge in that self-collection kits may be sent directly to a patient’s home instead of an investigator or home care specialist, and patients take on the process of collecting, potentially processing, and shipping samples back to the laboratory.

A variety of innovators are at various stages of blood self-collection device development. The information below is included to provide context for the reader and is not intended to be a comprehensive list or an endorsement of any specific device. For more information about individual devices, contact the manufacturers directly.

: Some devices require the use of a lancet and a finger prick. The following devices do not. The Tasso device is available in both dried blood spot and liquid collection formats. TAP, by Seventh Sense Biosystems, is available in a liquid collection format, and OneDrawTM from Drawbridge Health, is available in dried blood spot format.

: The following devices require a lancet, or have a self-contained lancet, and finger prick to collect via a dried blood spot format.

Clinical trial operational considerations

l: Of course, it all starts with patients and an unmet medical need, but protocols must consider the current state of self-collection devices, including their approval status in the jurisdictions needed, and the most appropriate applications. For example, in a recent study the protocol called for a liver panel a few days after an infusion visit. The protocol included both home phlebotomy and the use of self-collection devices. Another recent study specified the use of a blood self-collection device to be used by patients for home collection of a specimen needed for HbA1c testing. Study design and protocol writing will need to be carefully considered to expand the use of self-collection in clinical trials where appropriate.

: The specific device, and its regulatory status, the sample format (liquid or dried blood spot), approach to collection (lancet or device), location of collection (arm/thigh or finger), as well as the blood sample volumes required for the tests should be considered in developing the collection approach. The table below summarizes several of these attributes for the devices described earlier.

: Currently, most laboratory tests approved by regulatory authorities are primarily based on venous blood and not capillary blood used by the devices described above. We have found via correlation studies, that some analytes may require redefining specific reference ranges for capillary blood, serum, or plasma. From a clinical trial assay development perspective, pharmacokinetics (PK) and safety testing have emerged as target applications, but immunoassay and molecular tests are also being considered. There have been a considerable number of publications on PK testing via dried blood spot. As described above, one of the initial applications gaining traction is additional safety monitoring through the use of self-collection devices to increase sampling frequency without undue patient burden.

: Each of the devices are in a different state of readiness from a regulatory perspective. This is a dynamic landscape which must be assessed for each of the countries involved.

: Like traditional specimen collection kits, self-collection kits require visit and investigator information, air waybills and return boxes to facilitate return shipment. Barcoded labels will simplify processing at the destination laboratory.

: Some tests require centrifugation prior to shipment. Fortunately, small portable centrifuges, like the Sandstone Torq, and other potential innovations are under development and may be suitable for home use. Once available, consideration will need to be given to a centrifuge reutilization program, so that the right number of centrifuges are available at the right time for a study, to optimize cost and simplify logistics. Alternatively, work is ongoing to evaluate the impact of centrifugation at the lab instead of at the time of collection. It is likely that the results will vary by analyte.

: One option is to send the kit to the investigator to complete the demographic portion of the requisition and provide the device kits to patients. However, it may be preferable to have kits shipped directly to patients. Couriers should be chosen carefully to assure convenience of pick up time for patients. A shorter pick up time window is preferred by patients. Patients must also be counseled on any considerations about specimen stability and transit time from the point of collection.

: Laboratory tests require a minimum volume of blood, so the tests required by protocol will drive sample volume requirements, which in turn impacts the type and number of devices needed. Even with traditional blood collection in an office or clinic setting, limiting the required blood volume is a consideration in reducing patient burden. Self-collection may not be practical in all cases, particularly if the protocol requires a battery of tests with a need for high blood volumes.

: Manufacturer pain tolerance studies indicate that venous and finger stick collections are more painful and may be less preferred to the more novel approaches described earlier. Also, it may not be practical for all patients to use a lancet for self-collection.

: At the time of writing this article, Tasso is the only manufacturer to include removable standard tubes for liquid capillary blood collection on their website, but Seventh Sense Biosystems is also developing a device, TAP II, with standard removable tubes. While collection times vary by patient and device, our experience with the Tasso Serum Separator Tube (SST) devices showed that it takes an average of five minutes to collect about 300ul of blood, with similar claims made by Seventh Sense Biosystems for their TAP device. Depending on the testing and sample processing requirements, such as centrifugation, the complexity and number of devices could become a barrier.

: The complexity of pre-analytical sample processing requirements must be carefully considered. For example, removal of a tube out of a device like the Tasso SST, letting it sit for 30 minutes and then placing it in a centrifuge, may be too difficult for some patients, and may require innovative approaches to assure compliance. Additional studies and innovation may be needed to reduce this burden.

: Direct to patient (DtP) kit delivery and pick up options, including pick up windows, availability of dry ice, and access to white glove services vary significantly by location. Initial forays into self-collection of blood specimens in clinical trials may aim to limit patient burden with simpler sampling and sample processing requirements.

: This new paradigm of self-collection will likely require extra patient support. For example;

Kit and device receipt: Investigators and study teams will likely wish to assure support around the tracking of kit shipments to patients and receipt by patients.

Device use support: Patients may need assistance regarding the use of self-collection devices and the packaging and shipping of samples, which could take the form of live video support, video training for patients, and video training for investigator site staff.

Rapid resupply: Manufacturers data indicates that some percentage of the time a patient is unable to extract an adequate sample, therefore rapid resupply, potentially overnight, will be necessary to assure sampling windows are adhered to.

Nurse / phlebotomist rescue: If a patient is unable to extract an adequate sample, rapid deployment of a nurse or phlebotomist may be needed to assure sampling windows are adhered to.

: Certain laboratory tests require samples to be frozen at lower temperatures than residential freezer units permit, and it may not be practical to ask patients to store blood samples in a residential home freezer for health and safety reasons. Innovative approaches are under consideration, including carefully timed courier visits.

We recently completed a comparison of a 12-analyte chemistry panel using a Tasso-SST self-collection device and a Sandstone portable centrifuge. The study, which is being summarized for publication, consisted of 24 consented subjects, who had venous samples collected via a phlebotomist and capillary samples collected via self-collection. Sample sets were tested on the Roche Cobas 8000/c702 for a 12- Analyte Chemistry Panel, consisting of Total Protein, Albumin, Glucose, Sodium, Potassium, Chloride, Magnesium, Calcium, Phosphorus, Total Bilirubin, ALT and Enzymatic Creatinine. Overall, good correlation was observed, and examples are shown below.

Blood self-collection devices are in various states of regulatory approval and their utility varies by the amount of blood they can collect, processing requirements by test, and the creation of tests validated to appropriate regulatory standards and guidelines. The cost of the devices vary, as does the potential cost of patient support and courier fees, but when considering the cost of a site visit or a home visit by a healthcare professional, the cost of self-collection of a blood specimen for certain applications appears favorable. Once devices are perfected and operational processes are solidified, self-collection devices should have a bright future in providing utility for decreasing patient burden in clinical trials and supporting decentralized trial designs.

 is the Head of Decentralized Trial Solutions; 

 is the Global Director of Scientific Harmonization; 

 is the SVP of Global Head of Project Services; 

, is the VP of Strategy & Corporate Development; all of Q

Operational and patient burden considerations for self-collection of blood specimens in clinical trials

Self-collection of Blood Specimens in Clinical Trials

Laboratory point-of-care (POC) testing at investigator sites has been part of clinical trials for many years. Perhaps the most obvious example is pregnancy testing. Investigators also perform glucose tests and oxygen concentration tests, via pulse oximeters, at their sites. More recently, these tests can be performed at patient homes via innovative “connected” medical devices.

Over the past few years, there has been growth in the use of more complex POC laboratory devices in clinical trials. For example, devices have been deployed at investigator sites to screen and enroll a patient in a single visit, help reduce screen failure rates via a pre-screening step, and provide for results more rapidly than local labs.

. A therapeutic influenza study required patients to be diagnosed with influenza prior to enrollment. The sponsor was concerned that if patients went home after the screening visit to wait for lab results prior to enrollment, those patients who became sick might not be able to go back to the site to become enrolled. To solve this dilemma, an influenza A/B POC laboratory device was utilized at each investigator site to enable screening and enrolling in a single visit.

. A global chronic kidney disease trial used POC laboratory devices to test for estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) in a pre-screening step, which enabled subjects to be ruled out of a higher-cost screening process, ultimately reducing the screen failure rate.

. A rare disease study used a POC laboratory device to test for C-reactive protein (CRP) in order to rapidly identify patients who experienced “heart-attack-like” symptoms but were not having a myocardial infarction. As soon as symptoms were experienced, the patients went to the investigator site for an assessment. The availability of faster results via the POC device helped reduce medical risks and provided a screening approach for the study.

In each of these cases, the POC laboratory devices were used for screening, but device data was not submitted to regulatory authorities. Instead, samples were sent in parallel to the central laboratory company (central lab), a clinical trial laboratory with globally harmonized laboratory systems and processes. The central lab produced lab reports for the clinical trial investigators and performed the data transfers to sponsors, who need the data for regulatory filings.

Why don’t sponsors utilize data from the POC laboratory devices in regulatory filings?

Historically, regulators and sponsors were concerned that investigator site staff, even with ample training, may not operate, calibrate, and maintain devices in a manner that would assure consistent results. This perception varies greatly by geography, indication, and individual investigator site. As POC laboratory devices become easier to use, in part due to regulatory scrutiny, and with expanded training and accreditation for sites, this concern should dissipate.

In addition to concerns around the operation of POC laboratory devices, these devices do not enable sponsor study team members (e.g,,. medical monitors) to view lab reports or receive alerts regarding out-of-range results. In addition, the devices by themselves don’t enable clinical trial study teams to receive and process laboratory data needed for regulatory filings.

Integrating POC laboratory device data with clinical trial laboratory systems

In the patient care space outside of clinical trials, POC laboratory devices are routinely connected to hospital laboratory and physician systems and electronic medical records (EMR) systems. The same concept has been applied to the clinical trial laboratory testing environment by connecting these devices to clinical trial laboratory systems.

There are at least two methods of integrating POC laboratory device data into central lab systems to enable viewing of lab reports and centralizing data transfers. First, POC laboratory device lab reports (print outs) can be manually entered into the central laboratory system. Central labs use a similar approach for local lab data entry. (Local labs are laboratories used in clinical trials that are near the site and may be able to provide results faster than central labs, due to reduced transportation time.)

The drawback of manually entering lab report data is the time it takes for investigator sites to provide the lab reports (with reference ranges) to the central lab, and the time spent by lab personal on data entry and quality control checks. This may result in a delay in study team visibility to POC laboratory device results. Machine learning can be used to partially automate the data entry process, but there is still a reliance on the site personnel to provide the lab report in a timely manner.

A second approach is to adapt what is done in the healthcare space to the clinical trial ecosystem. Instead of connecting the POC laboratory devices to a hospital lab system, or EMR system, the devices can be connected directly to clinical trial laboratory systems.

The POC connectivity solution takes a POC laboratory device, like those available for chemistry analysis or complete blood count (CBC), and connects them to a cellular internet of things (IoT) router. This enables transmission of the device data via a virtual private network (VPN) to a middleware, which then sends the data to the central lab.

The central lab enables visibility of laboratory reports, alerts for out-of-range results, and centralized data transfers.

Will POC laboratory devices replace brick and mortar labs?

The elimination of brick and mortar labs does not seem to be on the horizon. Many tests can’t be performed by POC laboratory devices today. In some cases, sample processing may require experienced laboratory professionals or additional equipment, which may not be available in all settings. Even if technology overcomes the hurdles associated with specific tests and processing requirements, the high-volume capacity and automation at commercial labs, hospital labs, and clinical trial labs may create a barrier to acceptance of POC laboratory device testing due to cost concerns.

However, in certain situations, POC laboratory devices may have advantages. For example, if a patient is undergoing surgery in an operating room, a faster result may provide better patient care even in a hospital with a lab. Within clinical trials, investigator sites in remote locations may make it challenging to get samples to laboratories in a timely manner, assuring sample stability, or like the hospital example mentioned, require a more immediate result. As such, connecting POC laboratory devices to clinical trial laboratory systems may be advantageous. It is interesting to note that in clinical trials today, the need for faster results sometimes drives investigators and study teams to utilize local laboratories. Perhaps a similar connectivity model will be developed to connect local labs with central labs. Of course, combinability of local lab data may still be a challenge, since local labs working on a given study or program may not use the same instrumentation, SOPs, reference ranges, etc. It would be particularly challenging related to biomarker testing, especially in cases where sponsor-specific biomarkers are utilized.

The future of POC laboratory devices and home-based testing

Many companies are developing and honing POC laboratory devices, so test menus may continue to expand, and instrumentation may continue to be easier to use. For more information, consider Select Science1 for a list of 130+ devices, the American Association for Clinical Chemistry (AACC)2, and Point of Care Search3, which provides a test-based interface. Note that you will need to request information from the website proprietors.

Today, many companies are racing to develop complex POC devices, which someday may be used by patients to generate lab results at home, perhaps via their mobile phones. These more sophisticated devices aim to enable a fast-at-home CBC, chemistry analysis, or biomarker test with data and reference ranges analogous to those available at brick and mortar laboratories. While devices like this have not yet achieved regulatory approvals, this approach could be the way lab testing is performed in the future.

https://www.selectscience.net/point-of-care/product-directory

, MBA, Head of Alliance Management and Marketing; 

, PhD, Vice President, Strategy and Corporate Development; and 

, PhD, Vice President, Head of Digital Innovation; all of 

A look at the future of clinical trial laboratory testing amid the emerging use of new devices at the point of care.

Integration of Point-of-Care Devices in Clinical Trials

	Laboratory point of care (POC) testing at investigator sites has been part of clinical trials for many years. Perhaps the most obvious example is pregnancy testing. Investigators also perform glucose tests and oxygen concentration tests, via pulse oximeters, at their site. More recently, these tests can be performed at patient homes via innovative “connected” medical devices.

	Over the past few years, there has been growth in the use of more complex POC laboratory devices in clinical trials. For example, devices have been deployed at investigator sites to screen and enroll a patient in a single visit, help reduce screen failure rates via a pre-screening step, and provide for results more rapidly than local labs.

-A therapeutic influenza study required patients to be diagnosed with influenza prior to enrollment. The sponsor was concerned that if patients went home after the screening visit to wait for lab results prior to enrollment, those patients who became sick might not be able to go back to the site to become enrolled. To solve this dilemma, an influenza A/B POC laboratory device was utilized at each investigator site to enable screening and enrolling in a single visit.

-A global chronic kidney disease trial used POC laboratory devices to test for estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) in a pre-screening step, which enabled subjects to be ruled out of a higher-cost screening process, ultimately reducing the screen failure rate.

-A rare disease study used a POC laboratory device to test for C-Reactive Protein (CRP) in order to rapidly identify patients who experienced ‘heart-attack-like’ symptoms but were not having a myocardial infarction. As soon as symptoms were experienced, the patients went to the investigator site for an assessment. The availability of faster results via the POC device helped reduce medical risks and provided a screening approach for the study.

	In each of these cases, the POC laboratory devices were used for screening, but device data was not submitted to regulatory authorities. Instead, samples were sent in parallel to the central laboratory company (central lab), a clinical trial laboratory with globally harmonized laboratory systems and processes. The central lab produced lab reports for the clinical trial investigators and performed the data transfers to sponsors, who need the data for regulatory filings.

Why don’t sponsors utilize data from POC laboratory devices in regulatory ï¬lings?

	Historically, regulators and sponsors were concerned that investigator site staff, even with ample training, may not operate, calibrate, and maintain devices in a manner that would assure consistent results. This perception varies greatly by geography, indication, and individual investigator site. As POC laboratory devices become easier to use, in part due to regulatory scrutiny, and with expanded training and accreditation for investigator sites, this concern should dissipate.

	In addition to concerns around the operation of POC laboratory devices, these devices do not enable sponsor study team members (e.g. medical monitors) to view lab reports or receive alerts regarding out of range results. In addition, the devices by themselves don’t enable clinical trial study teams to receive and process laboratory data needed for regulatory filings.

	In the patient care space outside of clinical trials, POC laboratory devices are routinely connected to hospital laboratory and physician systems and electronic medical records (EMR) systems. The same concept has been applied to the clinical trial laboratory testing environment by connecting these devices to clinical trial laboratory systems.

There are at least two methods of integrating POC laboratory device data into central lab systems to enable viewing of lab reports and centralizing data transfers. First, POC laboratory device lab reports (print outs) can be manually entered into the central laboratory system. Central labs use a similar approach for local lab data entry. (Local labs are laboratories used in clinical trials that are near the investigator site and may be able to provide results faster than central labs, due to reduced transportation time.)

	The drawback of manually entering lab report data is the time it takes for investigator sites to provide the lab reports (with reference ranges) to the central lab, and the time spent by lab personal on data entry and quality control checks. This may result in a delay in study team visibility to POC laboratory device results. Machine learning can be used to partially automate the data entry process, but there is still a reliance on the investigator site personnel to provide the lab report in a timely manner.

	A second approach is to adapt what is done in the healthcare space to the clinical trial ecosystem. Instead of connecting the POC laboratory devices to a hospital lab system, or EMR system, the devices can be connected directly to clinical trial laboratory systems.

	The POC connectivity solution takes a POC laboratory device, like those available for chemistry analysis or complete blood count (CBC), and connects them to a cellular internet of things (IoT) router. This enables transmission of the device data via a virtual private network (VPN) to a middleware, which then sends the data to the central lab.

	The central lab enables visibility of laboratory reports, alerts for out of range results, and centralized data transfers.

	The elimination of brick and mortar labs does not seem to be on the horizon. Many tests can’t be performed by POC laboratory devices today. In some cases, sample processing may require experienced laboratory professionals or additional equipment, which may not be available in all settings. Even if technology overcomes the hurdles associated with specific tests and processing requirements, the high-volume capacity and automation at commercial labs, hospital labs and clinical trial labs may create a barrier to acceptance of POC laboratory device testing due to cost concerns.

	However, in certain situations, POC laboratory devices may have advantages. For example, if a patient is undergoing surgery in an operating room, a faster result may provide better patient care even in a hospital with a lab. Within clinical trials, investigator sites in remote locations may make it challenging to get samples to laboratories in a timely manner, assuring sample stability, or like the hospital example above, require a more immediate result. As such, connecting POC laboratory devices to clinical trial laboratory systems may be advantageous. It is interesting to note that in clinical trials today, the need for faster results sometimes drives investigators and study teams to utilize local laboratories. Perhaps a similar connectivity model will be developed to connect local labs with central labs. Of course, combinability of local lab data may still be a challenge, since local labs working on a given study or program may not use the same instrumentation, SOPs, reference ranges, etc. It would be particularly challenging related to biomarker testing, especially in cases where sponsor-specific biomarkers are utilized.

	The future of POC laboratory devices and home-based testing

	Many companies are developing and honing POC laboratory devices, so test menus may continue to expand, and instrumentation may continue to be easier to use. For more information, consider Select Science

for a list of 130+ devices, the American Association for Clinical Chemistry (AACC)

, which provides a test-based interface. Note that you will need to request information from the website proprietors.

	Today, many companies are racing to develop complex POC devices, which someday may be used by patients to generate lab results at home, perhaps via their mobile phones. These more sophisticated devices aim to enable a fast at home CBC, chemistry analysis, or biomarker test with data and reference ranges analogous to those available at brick and mortar laboratories. While devices like this have not yet achieved regulatory approvals, this approach could be the way lab testing is performed in the future.

, MBA, CA-AM, Head of Alliance Management and Marketing; 

, Vice President, Strategy & Corporate Development; and 

,  Vice President, Head of Digital Innovation all of Q2 Solutions.

Over the past few years, there has been significant growth in the use of more complex point of care laboratory devices. 

Chuck Drucker

Articles

At-home Self-collection of Blood Specimens for Safety Lab Testing in Clinical Trials via the Tasso+ Device

Self-collection of Blood Specimens in Clinical Trials

Integration of Point-of-Care Devices in Clinical Trials

Will Point of Care Laboratory Devices Replace Brick and Mortar Labs in Clinical Trials?